WO1993021169A1 - Benzothiazole-substituted benzyl alcohols as leukotriene antagonists - Google Patents

Abstract

Compounds having formula (I) are antagonists of the actions of leukotrienes. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.

Description

BENZOTHIAZOLE-SUBSTITTJTED BENZYL ALCOHOLS AS

LEUKOTRIENE ANTAGONISTS

BACKGROUND OF THE INVENTION

The leukotrienes constitute a group of locally acting hormones, produced in living systems from arachidonic acid. The major leukotrienes are Leukotriene B₄ (abbreviated at LTB₄), LTC₄, LTD₄, and LTE₄. The biosynthesis of these leukotrienes begins with the action of the enzyme 5-lipoxygenase on arachidonic acid to produce the epoxide known as Leukotriene A4 (LTA₄), which is converted to the other leukotrienes by subsequent enzymatic steps-Further details of the biosynthesis as well as the metabolism of the leukotrienes, are to be found in the book Leukotrienes and Lipoxygenases, ed. J.

Rokach, Elsevier, Amsterdam (1989). The actions of the leukotrienes in living systems and their

contribution to various diseases states are also discussed in the book by Rokach. U.S. Patent 4,957,932 (Sept. 18, 1990) discloses structures of leukotriene antagonists which differ from the present compounds in not having the benzyl alcohol. European patent application 404,440 (Dec. 27, 1990) describes benzothiazole-containing leukotriene biosynthesis inhibitors and/or

antagonists which differ from the present compounds, most notably by the presence of a chroman ring. The structures of the compounds disclosed in the above patent applications are shown below.

SUMMARY OF THE INVENTION

The present invention relates to

benzothiazole-substituted benzyl alcohols having activity as leukotriene antagonists, to methods for their preparation, and to methods and pharmaceutical formulations for using these compounds in mammals

(especially humans).

Because of their activity as leukotriene antagonists, the compounds of the present invention are useful as anti-asthmatic, anti-allergic,

anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection.

DETAILED DESCRIPTION OF THE INVENTION

The compounds of this invention are best realized by Formula I :

wherein :

R¹ is H , halogen , CN , lower alkyl , cyloakyl ,

polyhalo lower alkyl , lower alkoxy , lower alkoxy lower alkyl , lower alkylthio lower alkyl, lower alkenyl, substituted or

unsubstituted phenyl, pyridyl, thiazolyl, oxazolyl, furanyl or thienyl, or adjacent R¹'s and the carbons through which they are attached may form a saturated ring of 5 to

10 carbon atoms;

R² is lower alkyl, lower alkenyl, lower alkynyl,

-CF₃, -CH₂F, -CHF₂, -CH₂CF₃, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, substituted or unsubstituted 2-phenethyl, or two R² groups joined to the same carbon may form a saturated ring of up to 8 members containing 0 to 2 heteroatoms chosen from 0, S, and N; R³ is H or R²;

CR³R²² may be the radical of a standard amino acid; R⁴ is halogen, -NO_Z, -CN, -OR³, -SR³, NR³R³,

NR³C(O)R⁷, or R³;

R⁵ is H, halogen, -NO₂, -N₃, -CN, -SR², -NR³R³,

-OR³, lower alkyl, or -C(O)R³;

R⁶ is -(CH₂)_S-C(R⁷R⁷)-(CH₂)_S-R⁸ or -CH₂C(O)NR¹²R¹²; R⁷ is H or lower alkyl;

R⁸ is A) a monocyclic or bicyclic heterocyclic

radical containing from 3 to 12 nuclear carbon atoms and 1 or 2 nuclear heteroatoms selected from N, S or O and with each ring in the heterocyclic radical being formed of 5 or 6 atoms, or

B) the radical W-R⁹;

R⁹ contains up to 20 carbon atoms and is (1) an alkyl group or (2) an alkylcarbonyl group of an organic acyclic or monocyclic carboxylic acid containing not more than 1 heteroatom in the ring; R¹⁰ is -SR¹¹, -OR¹², or -NR¹²R¹²;

R¹¹ is lower alkyl, -C(O)R¹⁴, unsubstituted phenyl, or unsubstituted benzyl;

R¹² is H, R¹¹, or two R¹² groups joined to the same

N may form a saturated ring of 5 or 6 members containing up to two heteroatoms chosen from 0, S, and N;

R¹³ is lower alkyl, lower alkenyl, lower alkynyl,

-CF₃, or substituted or unsubstituted phenyl, benzyl, or 2-phenethyl;

R¹⁴ is H or R¹³;

R¹⁵ is R³ _or halogen;

R¹⁶ is H, lower alkyl, or OH;

R¹⁷ is lower alkyl, lower alkenyl, lower alkynyl, or substituted or unsubstituted phenyl, benzyl, or 2-phenethyl;

R¹⁸ is lower alkyl, lower alkenyl, lower alkynyl,

-CF₃, or substituted or unsubstituted phenyl, benzyl, or 2-phenethyl;

R¹⁹ is lower alkyl, lower alkenyl, lower alkynyl,

-CF₃, or substituted or unsubstituted phenyl, benzyl, or 2-phenethyl;

R²⁰ is H, lower alkyl, substituted or unsubstituted phenyl, benzyl, phenethyl, or pyridinyl, or two R²⁰ groups joined to the same N may form a saturated ring of 5 or 6 members containing one to two heteroatoms chosen from 0, S, and N;

R²¹ is H or R¹⁷;

R²² is R⁴, CHR⁷OR³, or CHR⁷SR²;

m and m' are independently 0-8;

p and p' are independently 0-8;

m + p is 1-10 when X² is O, S, S(O), or S(O)₂; m + p is 0-10 when X² is CR³R¹⁶ or a bond; m' + p' is 0-10;

s is 0-3;

Q¹ is -C(O)OR³, 1H (or 2H)-tetrazol-5-yl,

-C(O)OR⁶, -C(O)NHS(O)₂R¹³, -CN,

-C(O)NR¹²R¹², NR²¹S(O)₂R¹³,

-NR¹²C(O)NR¹²R¹², -NR²¹C(O)R¹⁸,

OC(O)NR¹²R¹², -C(O)R¹⁹, -S(O)R¹⁸, -S(O)₂R¹⁸, -S(O)₂NR¹²R¹², -NO₂, NR²¹C(O)OR¹⁷, -C(NR¹²R¹²)=NR¹², or -C(R¹³)=NOH; or if Q¹ is C(O)OH and R²² is -OH, -SH, CHR⁷OH or

-NHR³, then Q¹ and R²² and the carbons through which they are attached may form a heterocyclic ring by loss of water;

Q² is OR³;

W is O, S, or NR³;

X¹ is O, S, -S(O)-, -S(O)₂-, -N(R³)-, or -CR³R³-;

X² and X³ are independently O, S, S(O), S(O)₂,

CR³R¹⁶, or a bond;

Y is -CR³=CR³-, -C=C-, -CR³-X¹-, -X¹-CR³R³-,

-CR³R³-X¹-CR³R³-,

-C(O)-, -NR³C(O)-, -C(O)NR³-, O, S, NR³ , or

;

Z¹ and Z² are independently -HET(-R³-R⁵)- or a bond; HET is the diradical of a benzene, a pyridine, a furan, or a thiophene; or a pharmaceutically acceptable salt thereof.

More preferred compounds of Formula I are represented by Formula Ia:

wherein:

R¹ is H, halogen, CF₃, or lower alkoxy;

R²² is R³, -CH₂OR³, or -CH₂SR²;

Q¹ is -C(O)OH, 1H(or 2H)-tetrazol-5-yl,

-C(O)NHS(O)₂R¹³, -C(O)NR¹²R¹², or

-NHS(O)₂R¹³;

m' is 2 or 3;

p' is 0 or 1;

m + p is 1-5; and

the remaining definitions are as in Formula I; or a pharmaceutically acceptable salt thereof. The following abbreviations have the indicated meanings:

AIBN = 2,2'-azobis(isobutyronitrile) Py = 2-, 3-, or 4-pyridyl

Fu = 2- or 3-furanyl

Et = ethyl

Me = methyl

Bz = benzyl

Ph = phenyl

t-Bu = tert-butyl

i-Pr = isopropyl

n-Pr = normal propyl

c-Hex = cyclohexyl

c-Pr = cyclopropyl

c- = cyclo

Ac = acetyl

Tz = tetrasol-5-yl

Th = 2- or 3-thienyl

C₃H₅ = allyl

c-Pen = cyclopentyl

c-Bu = cyclobutyl

PPTS = pyridinium p-toluene sulfonate phe = benzenediyl

NBS = N-bromosuccinimide

NCS = N-chlorosuccinimide

pye = pyridinediyl

PTSA = p-toluenesulfonic acid

fur = furandiyl

r.t. = room temperature thio = thiophenediyl

DHP = 4H-2,3-dihydropyran

THP = tetrahydropyran The terms alkyl, alkenyl, and alkynyl mean linear and branched structures and combinations thereof.

The term "alkyl" includes "lower alkyl" and extends to cover carbon fragments having up to 20 carbon atoms. Examples of alkyl groups include octyl, nonyl, undecyl, dodecyl, tridecyl, tetradecyl, pentadecyl, eicosyl, 3,7-diethyl-2,2-dimethyl-4-propylnonyl, and the like.

The term "polyhalo" means one or more hydrogen atoms are replaced by halogen atoms.

The term "lower alkyl" means alkyl groups of from 1 to 7 carbon atoms. Examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, s- and t-butyl, pentyl, hexyl, heptyl, and the like.

The term "cycloalkyl" refers to a

hydrocarbon, containing one or more rings of from 3 to 12 carbon atoms, with the hydrocarbon having up to a total of 20 carbon atoms. Examples of cycloalkyl groups are cyclopropyl, cyclopentyl, cycloheptyl, aldamantyl, cyclododecylmethyl, 2-ethyl-1-bicyclo[4.4.0]decyl, and the like.

The term "alkenyl" includes "lower alkenyl" and means alkenyl groups of 2 to 20 carbon atoms . Examples of alkenyl groups include allyl,

5-decen-1-yl, 2-dodecen-l-yl, and the like.

"Lower alkenyl" means alkenyl groups of 2 to 7 carbon atoms. Examples of lower alkenyl groups include vinyl, allyl, isopropenyl, pentenyl, hexenyl, heptenyl, 1-propenyl, 2-butenyl, 2-methyl-2-butenyl, and the like.

"Cycloalkenyl" means alkenyl groups of 3 to 20 carbon atoms, which include a ring of 3 to 12 carbon atoms, and in which the alkenyl double bond may be located anywhere in the structure. Examples of cycloalkenyl groups are cyclopropen-1-yl,

cyclohexen-3-yl, 2-vinyladamant-1-yl, 5-methylenedodec-1-yl, and the like.

The term "alkynyl" includes "lower alkynyl" and means alkynyl groups of 2 to 20 carbon .atoms. Examples of alkynyl groups are ethynyl, 2-pentadecyn-1-yl, 1-eicosyn-1-yl, and the like.

"Lower alkynyl" means alkynyl groups of 2 to

7 carbon atoms. Examples of lower alkynyl groups include ethynyl, propargyl, 3-methyl-1-pentynyl, 2-heptynyl, and the like.

The term "cycloalkynyl" means alkynyl groups of 5 to 20 carbon atoms, which include a ring of 3 to 20 carbon atoms. The alkynyl triple bond may be located anywhere in the group, with the proviso that if it is within a ring, such a ring must be of 10 members or greater. Examples of cycloalkynyl are cyclododecyn-3-yl, 3-cyclohexyl-1-propyn-1-yl, and the like.

The term "lower alkoxy" means alkoxy groups of from 1 to 7 carbon atoms of a straight, branched, or cyclic configuration. Examples σf lower alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, cyclopropyloxy, cyclohexyloxy, and the like. The term "lower alkylthio" means alkylthio groups of from 1 to 7 carbon atoms of a straight, branched or cyclic configuration. Examples of lower alkylthio groups include methylthio, propylthio, isopropylthio, cycloheptylthio, etc. By way of illustration, the propylthio group signifies

-SCH₂CH₂CH₃.

The term "lower alkylsulfonyl" means alkylsulfonyl groups of from 1 to 7 carbon atoms of a straight, branched, or cyclic configuration.

Examples of lower alkylsulfonyl groups are

methylsulfonyl, 2-butylsulfonyl, cyclohexylmethylsulfonyl, etc. By way of illustration, the

2-butylsulfonyl group signifies -S(O)₂CH(CH₃)CH₂CH₃.

"Alkylcarbonyl" includes "lower

alkylcarbonyl" and means alkylcarbonyl groups of 1 to 20 carbon atoms of a straight, branched, or cyclic configuration. Examples of alkylcarbonyl groups are 2-methylbutanoyl, octadecanoyl, 11-cyclohexylundecanoyl, and the like. Thus, the 11-cyclohexylundecanoyl group is c-Hex-(CH₂)₁₀-C(O)-.

The term "lower alkylcarbonyl" means alkylcarbonyl groups of from 1 to 8 carbon atoms of a straight, branched, or cyclic configuration.

Examples of lower alkylcarbonyl groups are formyl, 2-methylbutanoyl, cyclohexylacetyl, etc. By way of illustration , the 2-methylbutanoyl groups signif ies -C(O)CH(CH₃)CH₂CH₃.

Substituted-phenyl, -benzyl, -2-phenethyl, or -pyridinyl means that the aromatic ring carries 1 or 2 substituents selected from lower alkyl, R¹⁰, NO₂, SCF₃, halogen, -C(O)R⁷, -C(O)R¹⁰, CN, CF₃, and Tz. Halogen includes F, Cl, Br, and I.

It is intended that the definitions of any substituent (e.g., R¹, R², R¹⁰, etc.) in a particular molecule be independent of its definitions elsewhere in the molecule. Thus, -NR¹²R¹² represents -NHH, -NHCH₃, -NHC₆H₅, etc.

The saturated rings formed when two R¹ groups join through two adjacent carbon atoms include c-pentane, c-hexane, c-heptane, c-octane, c-nonane, and c-decane.

The saturated rings formed when two R² groups join through C include c-propane, c-pentane, c-hexane, c-octane, tetrahydrofuran, tetrohydrothiophene, pyrrolidine, thiopyran, dioxan,

piperidine, morpholine, thiomorpholine, piperazine, and their N-lower alkyl analogs .

The heterocycles formed when two R¹² or R²⁰ groups join through N include pyrrolidine,

piperidine, morpholine, thiamorpholine, piperazine, and N-methylpiperazine.

When Q¹ and R²² and the carbons through which they are attached form a ring, the rings thus formed include lactones, lactams, and thiolactones .

The prodrug esters of Q¹ (i.e., when Q¹= CO₂R⁶) are intended to include the esters such as are described by Saari et al.. J. Med. Chem., 21, No. 8, 746-753 (1978), Sakamoto et al.. Chem. Pharm, Bull., 32, No. 6, 2241-2248 (1984), and Bundgaard et al ., J. Med. Chem., 30, No. 3, 451-454 (1987).

Within the definition of R⁸, some

representative monocyclic or bicyclic heterocyclic radicals are:

2, 5-dioxo-1-pyrrolidinyl,

(3-Pyridinylcarbonyl)amino, 1,3-dihydro-4,3-dioxo-2H-isoindol-2-yl,

1,3-dihydro-2H-isoindol-2-yl,

2,4-imidazolinedion-l-yl,

2,6-piperidinedion-l-yl,

2-imidazolyl,

2-oxo-1,3-dioxolen-4-yl,

piperidin-1-yl,

morpholin-1-yl, and

piperazin-1-yl.

"Standard amino acid", the radical of which may be CR³R²², means the following amino acids:

alanine, asparagine, aspartic acid, arginine,

cysteine, glutamic acid, glutamine, glycine,

histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. See F.H.C. Crick, Symposium of the Society of Experimental Biology, 12, 140 (1958). Optical Isomers - Diastereomers - Geometric Isomers

Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to diastereomers and optical isomers. The present invention is meant to comprehend such

possible diastereomers as well as their racemic and resolved, enantiomerically pure forms and

pharmaceutically acceptable salts thereof. Optically active (R) and (S) isomers may be resolved using conventional techniques.

Some of the compounds described herein contain olefinic double bonds, and unless specified otherwise, are meant to include both E and Z

geometric isomers. Salts

The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt, thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganic salts, manganous, potassium, sodium, zinc, and the like.

Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline,

N,N'-dibenzylethylenediamine, diethylamine,

2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine,

N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like. When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic,

benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric, gluconic, glutamic,

hydrobromic, hydrochloric, isethionic, lactic,

maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are citric,

hydrobromic, hydrochloric, maleic, phosphoric,

sulfuric, and tartaric acids.

It will be understood that in the discussion of methods of treatment which follows, references to the compounds of Formula I are meant to also include the pharmaceutically acceptable salts.

Utilities

The ability of the compounds of Formula I to antagonize the actions of the leukotrienes makes them useful for preventing or reversing the symptoms induced by the leukotrienes in a human subject. This antagonism of the actions of leukotrienes indicates that the compounds and pharmaceutical compositions thereof are useful to treat, prevent, or ameliorate in mammals and especially in humans: 1) pulmonary disorders including diseases such as asthma, chronic bronchitis, and related obstructive airway diseases, 2) allergies and allergic reactions such as allergic rhinitis, contact dermatitis, allergic conjunctivitis, and the like, 3) inflammation such as arthritis or inflammatory bowel disease, 4) pain, 5) skin

disorders such as psoriasis, atopic eczema, and the like, 6) cardiovascular disorders such as angina, myocardial ischemia, hypertension, platelet

aggregation and the like, 7) renal insufficiency arising from ischaemia induced by immunological or chemical (cyclosporin) etiology, 8) migraine or cluster headache, 9) ocular conditions such as uveitis, 10) hepatitis resulting from chemical, immunological or infectious stimuli, 11) trauma or shock states such as burn injuries, endotoxemia and the like, 12) allograft rejection, 13) prevention of side effects associated with therapeutic

administration of cytokines such as Interleukin II and tumor necrosis factor, 14) chronic lung diseases such as cystic fibrosis, bronchitis and other small- and large-airway diseases, and 15) cholecystitis.

Thus, the compounds of the present invention may also be used to treat or prevent mammalian

(especially, human) disease states such as erosive gastritis; erosive esophagitis; diarrhea; cerebral spasm; premature labor; spontaneous abortion;

dysmenorrhea; ischemia; noxious agent-induced damage or necrosis of hepatic, pancreatic, renal, or

myocardial tissue; liver parenchymal da-mage caused by hepatoxic agents such as CCI₄ and D- galactosamine; ischemic renal failure; disease-induced hepatic damage; bile salt induced pancreatic or gastric damage; trauma- or stress-induced cell damage; and glycerol-induced renal failure. The compounds also exhibit cytoprotective action. The cytoprotective activity of a compound may be observed in both animals and man by noting the increased resistance of the gastrointestinal mucosa to the noxious effects of strong irritants, for example, the ulcerogenic effects of aspirin or indomethacin. In addition to lessening the effect of non-steroidal anti-inflammatory drugs on the

gastrointestinal tract, animal studies show that cytoprotective compounds will prevent gastric lesions induced by oral administration of strong acids, strong bases, ethanol, hypertonic saline solutions, and the like.

Two assays can be used to measure

cytoprotective ability. These assays are; (A) an ethanol-induced lesion assay and (B) an

indomethacin-induced ulcer assay and are described in EP 140,684.

Dose Ranges

The magnitude of prophylactic or therapeutic dose of a compound of Formula I will, of course, vary with the nature of the severity of the condition to be treated and with the particular compound of

Formula I and its route of administration. It will also vary according to the age, weight and response of the individual patient. In general, the daily dose range for anti-asthmatic, anti-allergic or anti-inflammatory use and generally, uses other than cytoprotection, lie within the range of from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably 0.01 mg to about 10 mg per kg, and most preferably 0.1 to 1 mg per kg, in single or divided doses. On the other hand, it may be

necessary to use dosages outside these limits in some cases .

For use where a composition for intravenous administration is employed, a suitable dosage range for anti-asthmatic, anti-inflammatory, or anti-allergic use is from about 0.001 mg to about 25 mg (preferably from 0.01 mg to about 1 mg) of a compound of Formula I per kg of body weight per day and for cytoprotective use from about 0.1 mg to about 100 mg (preferably from about 1 mg to about 100 mg and more preferably from about 1 mg to about 10 mg) of a compound of Formula I per kg of body weight per day.

In the case where an oral composition is employed, a suitable dosage range for anti-asthmatic, anti-inflammatory or anti-allergic use is, e.g. from about 0.01 mg to about 100 mg of a compound of

Formula I per kg of body weight per day, preferably from about 0.1 mg to about 10 mg per kg and for cytoprotective use from 0.1 mg to about 100 mg

(preferably from about 1 mg to about 100 mg and more preferably from about 10 mg to about 100 mg) of a compound of Formula I per kg of body weight per day.

For the treatment of diseases of the eye, ophthalmic preparations for ocular administration comprising 0.001-1% by weight solutions or

suspensions of the compounds of Formula I in an acceptable ophthalmic formulation may be used.

The exact amount of a compound of the

Formula I to be used as a cytoprotective agent will depend on, inter alia, whether it is being administered to heal damaged cells or to avoid future damage, on the nature of the damaged cells (e.g., gastrointestinal ulcerations vs. nephrotic necrosis), and on the nature of the causative agent. An example of the use of a compound of the Formula I in avoiding future damage would be co-administration of a

compound of the Formula I with an NSAID that might otherwise cause such damage (for example,

indomethacin). For such use, the compound of Formula I is administered from 30 minutes prior up to 30 minutes after administration of the NSAID.

Preferably it is administered prior to or

simultaneously with the NSAID, (for example, in a combination dosage form).

Pharmaceutical Compositions

Any suitable route of administration may be employed for providing a mammal, especially a human with an effective dosage of a compound of the present invention. For example, oral, rectal, topical, parenteral, ocular, pulmonary, nasal, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions,

capsules, creams, ointments, aerosols, and the like.

The pharmaceutical compositions of the present invention comprise a compound of Formula I as an active ingredient or a pharmaceutically acceptable salt thereof, and may also contain a pharmaceutically acceptable carrier and optionally other therapeutic ingredients. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including

inorganic bases or acids and organic bases or acids. The compositions include compositions suitable for oral, rectal, topical, parenteral

(including subcutaneous, intramuscular, and

intravenous), ocular (ophthalmic), pulmonary (nasal or buccal inhalation) or nasal administration, although the most suitable route in any given case will depend on the nature and severity of the

conditions being treated and on the nature of the active ingredient. They may be conveniently

presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.

For administration by inhalation, the compounds of the present invention are conveniently delivered in the form of an aerosol spray

presentation from pressurized packs or nebulisers.

The compounds may also be delivered as powders which may be formulated and the powder composition may be inhaled with the aid of an insufflation powder inhaler device. The preferred delivery system for inhalation is a metered dose inhalation (MDI) aerosol, which may be formulated as a suspension or solution of a compound of Formula I in suitable propellants such as fluorocarbons or hydrocarbons.

Suitable topical formulations of a compound of formula I include transdermal devices, aerosols, creams, ointments, lotions, dusting powders, and the like.

In practical use, the compounds of Formula I can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety cf forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water,

glycols, oils, alcohols, flavoring agents,

preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, capsules and tablets, with the solid oral preparations being preferred over the liquid

preparations. Because of their ease of

administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously

employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.

In addition to the common dosage forms set out above, the compounds of Formula I may also be administered by controlled release means and/or delivery devices such as those described in U.S.

Patent Nos. 3,845,770; 3,916,899; 3,536,809;

3,598,123; 3,630,200 and 4,008,719, the disclosures of which are hereby incorporated herein by reference.

Pharmaceutical compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non-aqueous liquid, an oil-in-water emulsion or a water-in-oil liquid emulsion. Such compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association the active ingredient with the carrier which

constitutes one or more necessary ingredients. In general, the compositions are prepared by uniformly and intimately admixing the active ingredient with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation. For example, a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients. Compressed tablets may be prepared by compressing in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent. Desirably, each tablet contains from about 2.5 mg to about 500 mg of the active ingredient and each cachet or capsule contains from about 2.5 to about 500 mg of the active ingredient.

The following are examples of representative pharmaceutical dosage forms for the compounds of

Formula I :

Injectable Suspension (I.M.) mg/mL

Compound of Formula I 10

Methylcellulose 5.0

Tween 80 0.5

Benzyl alcohol 9.0

Benzalkonium chloride 1.0

Water for injection to a total volume of 1 mL

Tablet mg/tablet

Compound of Formula I 25

Microcrystalline Cellulose 415

Povidone 14.0

Pregelatinized Starch 43.5

Magnesium Stearate 2.5

500

Capsule mg/capguie

Compound of Formula I 25

Lactose Powder 573.5

Magnesium Stearate 1.5

600

Aerosol Per canister

Compound of Formula I 24 mg

Lecithin, NF Liquid Concentrate 1.2 mg

Trichlorofluoromethane, NF 4.025 g Dichlorodifluoromethane, NF 12.15 g Combinations with Other Drugs

In addition to the compounds of Formula I, the pharmaceutical compositions of the present invention can also contain other active ingredients, such as cyclooxygenase inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), peripheral

analgesic agents such as zomepirac diflunisal and the like. The weight ratio of the compound of the

Formula I to the second active ingredient may be varied and will depend upon the effective dose of each ingredient. Generally, an effective dose of each will be used. Thus, for example, when a

compound of the Formula I is combined with an NSAID the weight ratio of the compound of the Formula I to the NSAID will generally range from about 1000:1 to about 1:1000, preferably about 200:1 to about 1:200. Combinations cf a compound of the Formula I and other active ingredients will generally also be within the aforementioned range, but in each case, an effective dose of each active ingredient should be used.

NSAIDs can be characterized into five groups (1) propionic acid derivatives ;

(2) acetic acid derivatives;

(3) fenamic acid derivatives;

(4) oxicams; and

(5) biphenylcarboxylic acid derivatives, or a pharmaceutically acceptable salt thereof.

The propionic acid derivatives which may be used comprise: alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin, pirprofen,

prano-profen, suprofen, tiaprofenic acid, and

tioxaprofen. Structurally related propionic acid derivatives having similar analgesic and antiinflammatory properties are also intended to be included in this group.

Thus, "propionic acid derivatives" as defined herein are non-narcotic analgesics/

non-steroidal anti-inflammatory drugs having a free -CH(CH₃)COOH or -CH₂CH₂COOH group (which optionally can be in the form of a pharmaceutically acceptable salt group, e.g., -CH(CH₃)COO-Na⁺ or -CH₂CH₂COO-Na⁺), typically attached directly or via a carbonyl

function to a ring system, preferably to an aromatic ring system.

The acetic acid derivatives which may be used comprise: indomethacin, which is a preferred NSAID, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin, and zomepirac. Structually related acetic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

Thus, "acetic acid derivatives" as defined herein are non-narcotic analgesics/non-steroidal anti-inflammatory drugs having a free -CH₂COOH group (which optionally can be in the form of a

pharmaceutically acceptable salt group, e.g.

-CH₂COO-Na⁺), typically attached directly to a ring system, preferably to an aromatic or heteroaromatic ring system.

The fenamic acid derivatives which may be used comprise: flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid.

Structurally related fenamic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

Thus, "fenamic acid derivatives" as defined herein are non-narcotic analgesics/non-steroidal anti-inflammatory drugs which contain the basic structure:

which can bear a variety of substituents and in which the free -COOH group can be in the form of a

pharmaceutically acceptable salt group, e.g.,

-COO-Na⁺.

The biphenylcarboxylic acid derivatives which can be used comprise: diflunisal and

flufenisal. Structurally related biphenylcarboxylic acid derivatives having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

Thus, "biphenylcarboxylic acid derivatives" as defined herein are non-narcotic

analgesics/non-steroidal anti-inflammatory drugs which contain the basic structure:

which can bear a variety of substituents and in which the free -COOH group can be in the form of a

pharmaceutically acceptable salt group, e.g.,

-COO-Na⁺.

The oxicams which can be used in the present invention comprise: isoxicam, piroxicam, sudoxicam and tenoxican. Structurally related oxicams having similar analgesic and anti-inflammatory properties are also intended to be encompassed by this group.

Thus, "oxicams" as defined herein are non-narcotic analgesics/non-steroidal anti-inflammatory drugs which have the general formula:

wherein R is an aryl or heteroaryl ring system.

The following NSAIDs may also be used:

amfenac sodium, aminoprofen, anitrazafen,

antrafenine, auranofin, bendazac lysinate, benzydanine, beprozin, broperamole, bufezolac, cinmetacin, ciproquazone, cloximate, dazidamine, deboxamet, delmetacin, detomidine, dexindoprofen, diacerein, di-fisalamine, difenpyramide, emorfazone, enfenamic acid, enolicam, epirizole, etersalate, etodolac, etofenamate, fanetizole mesylate,

fenclorac, fendosal, fenflumizole, feprazone, floctafenine, flunixin, flunoxaprofen, fluproquazone, fopirtoline, fosfosal, furcloprofen, glucametacin, guaimesal, ibuproxam, isofezolac, isonixim,

isoprofen, isoxicam, lefetamine HCl, leflunomide, lofemizole, lonazolac calcium, lotifazole,

loxoprofen, lysin clonixinate, meclofenamate sodium, meseclazone, nabumetone, nictindole, nimesulide, orpanoxin, oxametacin, oxapadol, perisoxal citrate, pimeprofen, pimetacin, piproxen_* pirazolac,

pirfenidone, proglumetacin maleate, proquazone, pyridoxiprofen, sudoxicam, talmetacin, talniflumate, tenoxicam, thiazolinobutazone, thielavin B, tiaramide HCl, tiflamizole, timegadine, tolpadol, tryptamid, and ufenamate.

The following NSAIDs, designated by company code number (see e.g., Pharmaprojects), may also be used:

480156S, AA861, AD1590, AFP802, AFP860, AI77B, AP504, AU8001, BPPC, BW540C, CHINOIN 127, CN100, EB382, EL508, F1044, GV3658, ITF182, KCNTEI6090, KME4,

LA2851, MR714, MR897, MY309, 0N03144, PR823, PV102, PV108, R830, RS2131, SCR152, SH440, SIR133, SPAS510, SQ27239, ST281, SY6001, TA60, TAI-901 (4-benzoyl-1- indancarboxylic acid), TVX2706, U60257, UR2301, and WY41770. Finally, NSAIDs which may also be used include the salicylates, specifically acetyl

salicylic acid and the phenylbutazones, and

pharmaceutically acceptable salts thereof.

In addition to indomethacin, other preferred

NSAIDs are acetyl salicylic acid, diclofenac,

fenbufen, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, naproxen, phenylbutazone, piroxicam, sulindac, and tolmetin.

Pharmaceutical compositions comprising the

Formula I compounds may also contain inhibitors of the biosynthesis of the leukotrienes such as are disclosed in EP 138,481 (April 24,1985), EP 115,394 (August 8, 1984), EP 136,893 (April 10, 1985), and EP 140,709 (May 8, 1985), which are hereby incorporated herein by reference.

The compounds of the Formula I may also be used in combination with leukotriene antagonists such as those disclosed in EP 106,565 (April 25, 1984) and EP 104,885 (April 4, 1984) which are hereby

incorporated herein by reference and others known in the art such as those disclosed in EP Application Nos. 56,172 (July 21, 1982) and 61,800 (June 10, 1982); and in U.K. Patent Specification No. 2,058,785 (April 15, 1981), which are hereby incorporated herein by reference.

Pharmaceutical compositions comprising the Formula I compounds may also contain as the second active ingredient, prostaglandin antagonists such as those disclosed in EP 11,067 (May 28, 1980) or thromboxane antagonists such as those disclosed in U.S. Pat. 4,237,160. They may also contain histidine decarboxylase inhibitors such as α-fluoromethylhistidine, described in U.S. Pat. 4,325,961. The compounds of the Formula I may also be advantageously combined with an H₁- or H₂-receptor antagonist, such as for instance acetamazole, aminothiadiazoles disclosed in EP 40,696 (December 2, 1981), benadryl, cimetidine, famotidine, framamine, histadyl,

phenergan, ranitidine, terfenadine and like

compounds, such as those disclosed in U.S. Patent Nos. 4,283,408; 4,362,736; and 4,394,508. The pharmaceutical compositions may also contain a K⁺/H⁺ ATPase inhibitor such as omeprazole, disclosed in U.S. Pat. 4,255,431, and the like. Compounds of Formula I may also be usefully combined with most cell stabilizing agents, such as 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane and related

compounds described in British Patent Specifications 1,144,905 and 1,144,906. Another useful

pharmaceutical composition comprises the Formula I compounds in combination with serotonin antagonists such as methysergide, the- serotonin antagonists described in Nature. 316. 126-131 (1985), and the like. Each of the references referred to in this paragraph is hereby incorporated herein by reference.

Other advantageous pharmaceutical

compositions comprise the Formula I compounds in combination with anti-cholinergics such as

ipratropium bromide, bronchodilators such as the beta agonist salbutamol, metaproterenol, terbutaline, fenoterol and the like, and the anti-asthmatic drugs theophylline, choline theophyllinate and

enprofylline, the calcium antagonists nifedipine, diltiazem, nitrendipine, verapamil, nimodipine, felodipine, etc. and the corticosteroids,

hydrocortisone, methylprednisolone, betamethasone, dexamethasone, beclomethasone, and the like.

Methods of Synthesis

Compounds of the present invention can be prepared according to the following methods. Scheme 1

2-Halomethylbenzothiazole of general structure III is prepared by free radical halogenation of the commercially available, variously substituted, 2-methylbenzothiazole II with NCS or NBS in the presence of light and azo-iso-butyronitrile, or via the reaction of 2-aminothiophenols of general

structure IV with chloroacetyl chloride in the

presence of potassium carbonate. The resulting

2-halomethybenzothiazole is converted to the

corresponding phosphonium salt V by refluxing the former with triphenylphosphine in acetonitrile.

Scheme 2

Dialdehyde VI is half reduced with sodium borohydride. The resulting alcohol is protected as its tetrahydropyranyl ether VII which is then treated with vinyl magnesium bromide or allyl magnesium bromide to give the alcohol VIII. Coupling of VIII with bromide IX in the presence of palladium acetate gives the keto ester X. Reduction of the ketone with the complex XI (J. Am. Chem. Soc, 104. 5551-5553, 1987), followed by reaction of the ester with an alkyl Grignard or an alkyl cerium reagent, gives the diol XII. (To obtain compound XII with one R² = H, the initially formed ketone, after the addition of the first equivalent of Grignard reagent, is reduced to the corresponding benzyl alcohol.)

The chiral alcohol of the diol XII is first protected as the t-butyldimethyl silyl ether. The other benzylic alcohol is protected as a

tetrahydropyranyl ether which is then treated with tetrabutyl ammonium fluoride to give the alcohol XIII. Mesylation of XIII, followed by displacement of the resulting mesylate with the appropriate substituted thiol XIV, gives the thiol ether XV. Removal of the THP protecting groups from XV with PPTS in methanol followed by oxidation of the primary benzylic alcohol with manganese dioxide in ethyl acetate gives aldehyde' XVI. Coupling of V and XVI gives the olefin-linked benzothiazole benzyl alcohol XVII (I) .

Scheme 3

Reaction of XVII with trimethylsulfonium iodide and a base such as DMSO anion gives the

cyclopropyl linked compound XVIII (I). Reduction of the olefin of XVII with borane gives the saturated compound XIX (I) .

Starting from benzaldehyde XX and following the same sequence as described above for aldehyde VII, the compound XXI can be prepared which may be coupled with the halide III to give the ether linked benzothiazole benzyl alcohol XXII (I).

It will be obvious to one skilled in the art that compounds XVII, XVIII, XIX, and XXII having the opposite stereochemistry at the sulfur-bearing

benzylic carbon can be obtained by using the opposite stereoisomer of the reduction catalyst XI to reduce X to XII or by inversion of the stereocenter in XIII by a Mitsunobu reaction (Synthesis, 1-28, 1981). Scheme 4

Reduction of keto aldehyde XXIII, followed by protection of the corresponding alcohol as the tetrahydropyranyl ether, gives XXIV. The enolate of ketone XXIV, obtained by treatment of XXIV with a base such as KH or NaH is reacted with dimethylcarbonate to yield the ketoester XXV. Alkylation of XXV with iodide XXVI followed by decarboxylation of the resulting adduct using conditions such as heating with HC1 in acetic acid affords the ketone XXVII. In the case where the THP ether is cleaved, the alcohol is reprotected as the THP ether. Following the procedure described in Scheme 2, ketone XXVII is transformed to XXVIII, a structure representative of I.

Scheme 5

Iodoacid XXIX is treated with 2 equivalents of a base such as n-butyllithium in a suitable solvent such as THF at -100°C, then at -78°C to afford XXX, which is reacted with aldehyde VII to yield the hydroxyacid XXXI. The hydroxyacid XXXI is then esterified using conditions such as CH₂N₂ or MeI/Cs₂CO₃, and an organometallic reagent is then added to give the diol XXXII. Following the same procedure as described in Scheme 2, the benzylic alcohol is transformed to XXXIII, which is a

structure representative of I.

T

Representative Compounds

Table I illustrates compounds of formula lb, which are representative of the present invention.

TABLE I

EX. * R¹ R¹ Y A B

1 R H H CH=CH (CH₂)₂(1,2)phe)C(Mr)₂OH SCH₂C(CH₂)₂CH₂CO₂H

2 R 5-F H CH=CH (CH₂)₂(1,2-phe)C(Me)₂OH SCH₂G(CH₂)₂CH₂CO₂H

3 R 5-C1 H CH=CH (CH₂)₂(1,2-phe)C(ME)₂OH SCH₂C(CH2)₂CH₂CO₂H

4 R 5-CF₃ H CH=CH (CH₂)₂(1,2-phe)C(ME)₂OH SCH₂C(CH₂)₂CH₂CO₂H

5 R 5-F 6-F CH=CH (CH₂)₂(1,2-phe)C(ME)₂OH SCH₂C(CH₂)₂CH₂CO₂H

6 R H 6-OMe CH=CH (CH₂)₂(1,2-phe)C(ME)₂OH SCH₂C(CH₂)₂CH₂CO₂H

7 R 5-F 6-GF₃ CH₂CH₂ (CH₂)₂(4-C1-1,2-phe)C(ME)₂OH OCH₂C(CH3 ) ₂CH₂CO₂H

8 S 5-F 6-CF₃ CH₂O (CH₂)₂(4 -Cl-l,2-phe)C(ME)₂OH OCH₂CH(CH₃)CH₂Tz

9 R 5-CF₃ 6-F CH(-CH₂-)CH (CH₂)₂(4 -F-1,2-phe)C(ME)₂OH SCH₂CH(C₂H₅)CH₂CONMe₂

10 S 5-CF3 6-CF₃ CH(CH₃)CH(CH₃) (CH₂)₂(4 -F-4,2-phe)CMePhOH SCH₂CH₂CO₂H

11 RS H 6-F CH(-C(CH₃)₂-)CH (CH₂)₂(3 -C1-1,2-phe)CHMeOH SCH₂CH₂CONHS(O)₂Ph

12 R 5-F 6-G1 CH₂S (CH₂)₂(5 -F-1,2-phe)CMeGF₃OH SCH₂CH₂CONHS(O)₂CH₃

13 RS 5-C1 6-GF CH(CH₃)CH₂ (6-CF₃-1,2-phe)CHCF₃OH SCH₂CH₂CONHS(O)₂CF₃

14 S 5-G1 6-G1 CH=CH (CH₂)₂(4-CF3-1,2-phe)C(CF₃)₂OH SCH₂C(CH₂)₂CH₂CONHS(O)₂Ph

15 R 5-F 6-F CH₂CH₂ (CH₂)₂(4 -F-1,3-phe)CMeEtOH CH₂Ce₂C(CH3)₂CO₂H

16 R 5-F H CH₂CH₂ (CH₂)₂(4,-F-1,4-phe)C(CH₂)₂OH SCH₂CH(C₂H₅)Tz

17 R 5-C1 H CH=CH (CH₂)₂(4-F-1,2-phe)C(CH₂)₃OH SCH₂C(CH₂)₂NHS(O)₂CF₃

18 S 5-F H CH=CH (CH₂)₂(4-F-1,2-phe)C(CH₂)₄OH SCH₂C(GH₂)3CH₂CO₂H

19 R 5-C1 H CH₂CH₂ (CH₂)₂(4-F-1,2-phe)C(CH₂)₅OH SCH₂C(GH₂)₄CH₂CO₂H

20 S 5-CF₃ H CH₂O (CH₂)₂(2,5-fur)C(Me)₂OH SCH₂C(CH₂)₅CH₂CO₂H

21 RS 5-F 6-F CH(-CH₂-)CH (CH₂)₂(1,2-phe)C(Me)₂OH SCH₂C(CH3)₂CH₂CO₂H

22 R 5-F 6-F CH(CH₃)CH(CH₃) (CH₂)₂(2,5-thio)C(Me)₂OH SCH₂CH(CH₃;CH₂Tz

23 R 5-F H CH(-C(CH₃)₂-)GH (CH₂)₂(2,6-pye)C(Me)₂OH SCH₂CH(C₂H₅)CH₂CONMe₂

24 R 5-C1 H CH₂S (CH₂)₂(2,4-pye)C(Me)₂OH SCH₂CH₂CO₂H

25 R 4-c-Bu H CH=CH (CH₂)₂(1,2-phe)C(Me)₂OH SCH₂C(CH₂)₂GH₂CO₂H

26 R 4-CN H CH=CH (CH₂)₂(1,2-phe)C(Me)₂OH SCH₂C(CH₂)₂CH₂CO₂H

Assays for Determining Biological Activity

The leukotriene antagonist properties of the compounds of the present invention are evaluated using the following assays.

Three assays are described in T.R. Jones et al., Can. J. Physiol. Pharmacol., 1989. 67, 17-28. These are:

1) LTD₄ Receptor Binding Assays in Guinea Pig Lung Membranes,

2) Guinea Pig Trachea, and

3) In Vivo Assays in Anesthetized Guinea Pigs

Asthmatic Rat Assay

Rats are obtained from an inbred line of asthmatic rats. Both female (190-250 g) and male (260-400 g) rats are used.

Egg albumin (EA), grade V, crystallized and lyophilized, is obtained from Sigma Chemical Co., St. Louis. Aluminum hydroxide is obtained from the Regis Chemical Company, Chicago. Methysergide bimaleate is supplied by Sandoz Ltd., Basel.

The challenge and subsequent respiratory recordings are carried out in a clear plastic box with internal dimensions 10×6×4 inches. The top of the box is removable; in use, it is held firmly in place by four clamps and an airtight seal is

maintained by a soft rubber gasket. Through the center of each end of the chamber a DeVilbiss nebulizer (No. 40) is inserted via an airtight seal and each end of the box also has an outlet. A

Fleisch No. 0000 pneumotachograph is inserted into one end of the box and coupled to a Grass volumetric pressure transducer (PT5-A) which is then connected to a Beckman Type R Dynograph through appropriate couplers. While aerosolizing the antigen, the outlets are open and the pneumotachograph is isolated from the chamber. The outlets are closed and the pneumotachograph and the chamber are connected during the recording of the respiratory patterns. For challenge, 2 mL of a 3% solution of antigen in saline is placed into each nebulizer and the aerosol is generated with air from a small Potter diaphragm pump operating at 10 psi and a flow of 8 liters/minute.

Rats are sensitized by injecting

(subcutaneously) 1 mL of a suspension containing 1 mg EA and 200 mg aluminum hydroxide in saline. They are used between days 12 and 24 postsensitization. In order to eliminate the serotonin component of the response, rats are pretreated intravenously 5 minutes prior to aerosol challenge with 3.0 mg/kg of

methysergide. Rats are then exposed to an aerosol of 37β EA in saline for exactly 1 minute, then their respiratory profiles are recorded for a further 30 minutes. The duration of continuous dyspnea is measured from the respiratory recordings.

Compounds are generally administered either orally 1-4 hours prior to challenge or intravenously 2 minutes prior to challenge. They are either dissolved in saline or 1% methocel or suspended in 1% methocel. The volume injected is 1 mL/kg (intravenously) or 10 mL/kg (orally). Prior to oral treatment rats are starved overnight. Their activity is determined in terms of their ability to decrease the duration of symptoms of dyspnea in comparison with a group of vehicle-treated controls. Usually, a compound is evaluated at a series of doses and an ED₅₀ is determined. This is defined as the dose (mg/kg) which would inhibit the duration of symptoms by 50%.

Pulmonary Mechanics in Trained Conscious Squirrel

Monkeys

The test procedure involves placing trained squirrel monkeys in chairs in aerosol exposure

chambers. For control purposes, pulmonary mechanics measurements of respiratory parameters are recorded for a period of about 30 minutes to establish each monkey's normal control values for that day. For oral administration, compounds are dissolved or suspended in a 1% methocel solution (methylcellulose, 65HG, 400 cps) and given in a volume of 1 mL/kg body weight. For aerosol administration of compounds, a DeVilbiss ultrasonic nebulizer is utilized. Pretreatment periods vary from 5 minutes to 4 hours before the monkeys are challenged with aerosol doses of either leukotriene D4 (LTD₄) or Ascaris suum antigen.

Following challenge, each minute of data is calculated by computer as a percent change from control values for each respiratory parameter

including airway resistance (RL) and dynamic

compliance (C_dyn). The results for each test compound are subsequently obtained for a minimum period of 60 minutes post challenge which are then compared to previously obtained historical baseline control values for that monkey. In addition, the overall values for 60 minutes post-challenge for each monkey (historical baseline values and test values) are averaged separately and are used to calculate the overall percent inhibition of LTD₄ or Ascaris antigen response by the test compound. For statistical analysis, paired t-test is used. (References:

McFarlane, C.S. et al., Prostaglandins, 28, 173-182 (1984) and McFarlane, C.S. et al ., Agents Actions, 22, 63-68 (1987).)

Prevention of Induced Bronchoconstriction in Allergic Sheep

A. Rationale:

Certain allergic sheep with known

sensitivity to a specific antigen (Ascaris suum) respond to inhalation challenge with acute and late bronchial responses. The time course of both the acute and the late bronchial responses approximates the time course observed in asthmatics and the pharmacological modification of both responses is similar to that found in man. The effects of antigen in these sheep are largely observed in the large airways and are conveniently monitored as changes in lung resistance or specific lung resistance.

B. Methods:

Animal Preparation: Adult sheep with a mean weight of 35 kg (range, 18 to 50 kg) are used. All animals used meet two criteria: a) they have a natural cutaneous reaction to 1:1,000 or 1:10,000 dilutions of Ascaris suum extract (Greer Diagnostics, Lenois, NC) and b) they have previously responded to inhalation challenge with Ascaris suum with both an acute bronchoconstriction and a late bronchial obstruction (W.M. Abraham et a l . , Am. Rev. Resp.

Dis., 128, 839-44 (1983)).

Measurement of Airway Mechanics: The unsedated sheep are restrained in a cart in the prone position with their heads immobilized. After topical anesthesia of the nasal passages with 2% lidocaine solution, a balloon catheter is advanced through one nostril into the lower esophagus. The animals are then intubated with a cuffed endotracheal tube through the other nostril using a flexible fiberoptic bronchoscope as a guide. Pleural pressure is

estimated with the esophageal balloon catheter

(filled with one ml of air), which is positioned such that inspiration produces a negative pressure

deflection with clearly discernible cardiogenic oscillations. Lateral pressure in the trachea is measured with a sidehole catheter (inner dimension, 2.5 mm) advanced through and positioned distal to the tip of the nasotracheal tube. Transpulmonary

pressure, the difference between tracheal pressure and pleural pressure, is measured with a differential pressure transducer (DP45; Validyne Corp.,

Northridge, CA). For the measurement of pulmonary resistance (R_L), the maximal end of the nasotrachel tube is connected to a pneumotachograph (Fleisch, Dyna Sciences, Blue Bell, PA). The signals of flow and transpulmonary pressure are recorded on an oscilloscope (Model DR-12; Electronics for Medicine, White Plains, NY) which is linked to a PDP-11 Digital computer (Digital Equipment Corp., Maynard, MA) for on-line calculation of R^ from transpulmonary

pressure, respiratory volume obtained by integration and flow. Analysis of 10-15 breaths is used for the determination of R_L. Thoracic gas volume (V_tg) is measured in a body plethysmograph, to obtain specific pulmonary resistance (SR_L = R_L•v_tg) .

Aerosol Delivery Systems: Aerosols of

Ascaris suum extract (1:20) are generated using a disposable medicalnebulizer (Raindrop®, Puritan

Bennett), which produces an aerosol with a mass median aerodynamic diameter of 6.2 μ-M (geometric standard deviation, 2.1) as determined by an electric size analyzer (Model 3030; Thermal Systems, St. Paul, MN). The output from the nebulizer is directed into a plastic t-piece, one end of which is attached to the nasotracheal tube, the other end of which is conected to the inspiratory part of a Harvard

respirator. The aerosol is delivered at a tidal volume of 500 mL of a rate of 20 per minute. Thus, each sheep receives an equivalent dose of antigen in both placebo and drug trials.

Experimental Protocol: Prior to antigen challenge baseline measurements of SR_L are obtained, infusion of the test compound is started 1 hr prior to challenge, the measurement of SR_L repeated and then the sheep undergoes inhalation challenge with Ascaris suum antigen. Measurements of SR_L are obtained immediately after antigen challenge and at 1, 2, 3, 4, 5, 6, 6.5, 7, 7.5, and 8 hrs after antigen challange. Placebo and drug tests are separated by at least 14 days. In a further study, sheep are given a bolus dose of the test compound followed by an infusion of the test compound for 0.5-1 hr prior to Ascaris challenge and for 8 hrs after Ascaris as described above.

Statistical Analysis: A Kruskal-Wallis one way ANOVA test is used to compare the acute immediate responses to antigen and the peak late response in the controls and the drug treated animals.

The invention is further defined by the following non-limiting examples in which, unless stated otherwise:

(i) all operations were carried out at room or ambient temperature, that is, at a temperature in the range 18-25°C;

(ii) evaporation of solvent was carried out using a rotary evaporator under reduced pressure (600-4000 pascals: 4.5-30 mm. Hg) with a bath temperature of up to 60ºC;

(iii) the course of reactions was followed by thin layer chromatography (TLC) and reaction times are given for illustration only;

(iv) melting points are uncorrected and 'd'

indicates decomposition; the melting points given are those obtained for the materials prepared as described; polymorphism may result in isolation of materials with

different melting points in some

preparations;

(v) all final products were essentially pure by TLC and had satisfactory nuclear magnetic resonance (NMR) spectra and microanalytical data;

(vi) yields are given for illustration only and, for crystalline end-products, refer to the weight of recrystallized solid;

(vii) when given, NMR data are in the form of

delta (δ) values for major diagnostic

protons, given in parts per million (ppm) relative to tetramethylsilane (TMS) as internal standard, determined at 250 MHz or 300 MHz using the indicated solvent;

conventional abbreviations for signal shape are used (for example, s. singlet; d. doublet; m. multiplet; br. broad); "Ar" signifies an aromatic signal;

(viii) chemical symbols have their usual meanings;

the following abbreviations have also been used: v (volume), w (weight), b.p. (boiling point), m.p. (melting point), L (liter(s)), mL (milliliters), g (gram(s)), mg

(milligram(s)), mol (moles), mmol

(millimoles), eq. (equivalents)), (hour(s)). EXAMPLE 1

Sodium 1-(((1(R)-((3-(2-(2-benzothiazolyl)ethenyl)-phenyl)-3-(2-(1-hydroxy-1-methyl)ethyl)phenyl)propyl) thio)methyl)cyclopropaneacetate

Step 1: 2-Bromomethylbenzothiazole

To a solution of 2-methylbenzothiazole (29.8 g, 200 mmol) in CCI₄ (500 mL) was added NBS (43 g, 240 mmol) and AIBN (40 mg, 0.24 mmol). The mixture was photolysed with two flood lamps (500 W) for 6 hr with stirring, cooled and filtered through celite. The filtrate was concentrated in vacuo and the crude oil was chromatographed on silica gel (eluted with

toluene) to give 18.5 g (327..) of the title compound.

Step 2: 2-Benzothiazolylmethyl triphenylphosphonium

bromide

To a solution of 2-bromomethylbenzothiazole from Step 1 (2.28 g, 10 mmol) in CH₃CN (30 mL) was added P(Ph)₃ (5.24 g, 20 mmol). The mixture was refluxed for 20 h and was then concentrated to 1/3 of its original volume. Et₂O (20 mL) was added. The mixture was stirred vigorously and the crystalline salt was filtered and washed with more Et₂O to give 4.1 g (84%) of the title compound. Step 3 : 1.1-Cycloρroρanedimethanol cyclic sulfite

To a solution of BH₃:THF complex (1M in THF, 262 mL) was added diethyl 1,1-cyclopropanedicarboxylate (25 g, 134 mmol) at 25°C under N_2. The solution was heated at reflux for 6 hr, cooled to r.t., and MeOH (300 mL) was cautiously added. The solution was stirred for 1 hr and then concentrated to an oil. The crude diol was dissolved in CH₂CI₂ (234 mL) and SOCl₂ (15.9 g, 134 mmol) was added dropwise over a period of 15 min at 25ºC. After stirring for another 15 min, the mixture was washed with aqueous NaHCO₃. The organic extract was dried over Na₂SO₄, filtered and concentrated to give quantitatively the title compound as a white solid.

Step 4: 1-(Hyroxymethyl)cyclopropaneacetonitrile

To a solution of the cyclic sulfite product of Step 3 (14.7 g, 99 mmol) in DMF (83 mL) was added NaCN (9.74 g, 199 mmol). The mixture was heated to 90ºC for 20 hr. Upon cooling, EtOAc (400 mL) was added and the solution was washed with saturated NaHCO₃ solution (55 mL), H₂O (4× 55 mL), saturated NaCl solution, and dried over Na₂SO₄. The solution was concentrated to give 7.1 g (657o) of the title compound. Step 5 : 1-(Acetythiomethyl)cyclopropaneacetonitrile

To a solution of the alcohol of Step 4 (42 g, 378 mmol) in dry CH₂Cl₂ (450 mL) at -30°C was added Et₃N (103.7 mL, 741 mmol) followed by CH₃SO₂Cl (43.3 mL, 562 mmol) dropwise. The mixture was warmed to 25ºC, washed with NaHCO₃, dried over Na₂SO₄, and concentrated in vacuo to give the corresponding mesylate. The mesylate was then dissolved in DMF (450 mL) and cooled to 0°C. Potassium thioacetate (55.4 g, 485 mmol) was added, and the mixture was stirred at 25°C for 18 hr EtOAc (1.5 L) was added, the solution was washed with NaHCO₃, dried over

Na₂SO₄, and concentrated in vacuo to give 45 g (70%) of the title compound.

Step 6: Mettiyl 1-(thiomethyl)cyclopropaneacetate

To a solution of the nitrile of Step 6 (45 g, 266 mmol) in MeOH (1.36 L) was added H₂O (84 mL) and cone. H₂SO₄ (168 mL). The mixture was heated to reflux for 20 hr, cooled to 25ºC, H₂O (1 L) was added, and the product was extracted with CH₂CI₂ (2× 1.5 L). The organic extract was washed with H₂O and dried over Na₂SO₄ Concentration of the organic solution gave 36 g (93%) of the title compound.

Step 7: 3-(2-Tetrahydropyranyl)oxymethyl benzaldehyde

Isophthalaldehyde (150 g, 1.1 mole) was dissolved in THF (1 L) and EtOH (1 L) at 0°C. NaBH₄ (11.0 g, 291 mmol) was added portionwise and the mixture stirred 1 hour at 0°C. Addition of 25% aq. NH₄OAC and extraction with EtOAc (2x) followed by purification by flash chromatography (20% -> 40% EtOAc in hexanes) yielded 60 g of m-hydroxymethyl

benzaldehyde.

This alcohol (0.44 mole) was dissolved in CH₂Cl₂ (500 ml), DHP (50 g, 0.59 mole) and PTSA (1 g, 5 mmol) were added and the mixture was stirred

overnight at r.t. After concentration in vacuo, the residue was purified by flash chromatography (5%→ 15% EtOAc in toluene) to give 85 g of the title compound.

Step 8 : 1-((3-(2-Tetrahydropyranyl)oxymethyl)phenyl)- pro-2-ene-1-ol

To the aldehyde of Step 7 (85 g, 386 mmol) in toluene (1 L) at 0ºC was slowly added vinyl

magnesium bromide in Et₂O (450 ml, 1 M, 450 mmol) over a 30 minute period. After stirring for 1 hour, the reaction mixture was quenched with 25% aq. NH₄OAC and extracted with EtOAc (3x). Evaporation and purification by flash chromatography (15%→ 25% EtOAc in.toluene) yielded 82 g (86%) of the title compound.

Step 9: Ethyl 2-((3-(3-(2-tetrahydropyranyl)oxymethyl)phenyl)-3-oxo))propylbenzoate

The allylic alcohol of Step 8 (24.8 g, 100 mmol) and ethyl o-bromobenzoate (25.2 g, 110 mmol) were dissolved in DMF (200 mL). LiCl (4.2 g, 100 mmol), LiOAc•2H₂O (25.5 g, 250 mmol) and n-Bu₄N+C1- (55 g, 200 mmol) were added and the resulting mixture was degassed three times. Pd(OAc)2 (1 g) was then added and the mixture was degassed three more times before heating it at 100ºC with stirring for 1 hour. After cooling to r.t., the reaction mixture was poured onto H₂O (600 mL), 10% aq. NaHCO₃ (200 mL) and Et₂O. The crude product was extracted with Et₂O (2x), washed with H₂O and brine, and dried over Na₂SO₄ before concentrating in vacuo. Purification on a short silica gel column (20%. EtOAc in hexanes) gave 34 g (86%) of the title compound.

¹H NMR (CD₃COCD₃): δ 8.02 (1H, bs), 7.92 (1H, d), 7.88 (1H, d), 7.65 (1H, d), 7.50 (3H, m), 7.32 (1H, bt), 4.8 (1H, d), 4.70 (1H, bs), 4.54 (1H, d), 4.3 (2H, q), 3.82 (1H, m), 3.50 (1H, m), 3.35 (4H, m), 1.9-1.45 (6H, m), 1.32 (3H, t).

Step 10: 1(S)-Ethyl 2-(3-hydroxy-3-((3-(2-tetrahydropyranyl)oxymethyl)phenyl)propyl benzoate

The keto-ester of Step 9 (24.8 g, 62.5 mmol) was dissolved in THF (230 mL) and cooled to -45ºC. A THF (15 ml) solution of tetrahydro-1-methyl-3,3-diphenyl-1H, 3H-pyrrolo[1,2-c][1,3,2]oxazoboroleborene adduct (J. Org. Chem. 56., 751 (1991), 4.55 g, 15.6 mmol) was added dropwise and the resulting mixture was stirred 20 minutes at -45ºC. To this solution, 1.0M borane in THF (62.5 mL, 62.5 mmol) was added dropwise over 30 minutes. The reaction mixture was stirred 1 hour at -45°C followed by another 2 hours with slow warming to -20°C. After cooling the solution to -40°C, it was poured onto 25% aq. NH₄OAC (425 mL) and 1.0 M diethanolamine (40 mL) at 0°C and stirred vigorously for 20 minutes. The title

compound was extracted with EtOAc (3x), dried over MgSO₄ and concentrated under reduced pressure. The crude oil was purified by flash chromatography (25% to 50% EtOAc in hexanes) to yield 22.6 g (91%) of the product as an oil.

[α]_D ²⁵ = -32.6° (C = 3, CHCI₃)

Step 11: 1(S)-((3-(2-Tetrahydropyranyl)oxymethyl)- phenyl)-3-((2-(1-hydroxy-1-methyl)ethyl)- phenyl)propan-1-ol

Anhydrous CeCl₃ (17.25 g, 70 mmol) was refluxed for 2.5 hours in THF (200 mL) using a DeanStark trap filled with molecular sieves to remove H₂O. The ivory suspension was cooled to -5ºC and MeMgCl (114 mL, 3 M in THF, 340 mmol) was added dropwise while keeping the internal temperature between -10ºC and 0ºC. The grey suspension was stirred 2 hours before slowly adding to it the hydroxy-ester of Step 10 (27.1 g, 68 mmol) as a THF solution (200 mL) via a cannula. The resulting mixture was stirred 1.5 hours at or below 0ºC, and then slowly poured onto ice cold 1M HOAc (1 L) and EtOAc (500 ml) and stirred for 30 minutes. After adjusting the pH to 6-7, the crude compound was extracted with EtOAc (2x) and the combined organic phases were washed with saturated NaHCO₃ aq. followed with brine. Purification on a short silica gel column (30% to 50% EtOAc in hexanes) yielded 24.5 g (95%) of the title compound.

Step 12: Methyl 1-(((1(R)-((3-(2-tetrahydropyranyl)- oxymethyl)phenyl))-3-(2-(1-hydroxy-1-methyl)- ethyl)phenyl)thio)methyl)cyclopropaneacetate

The diol of Step 11 (17.9 g, 46.6 mmol) was dissolved in CH₃CN (40 mL) and DMF (10 mL) and cooled to -42°C under nitrogen. Diisopropylethylamine (8.5 mL, 48.9 mmol) was added followed by methanesulphonyl chloride (3.6 mL, 46.6 mmol) dropwise. The solution was stirred 1.5 hours with a mechanical stirring while maintaining the temperature between -42° and -35ºC; then it was cooled to -45°C. The thiol of Step 6 (7.84 g, 48.9 mmol) was added followed by dropwise addition of DMF (15 mL). Potassium

tertbutoxide in THF (56 mL, 1.75 M, 97.9 mmol) was added to the reaction mixture over 20 minutes using a syringe pump. Stirring was continued for 5 hours with slow warming from -35°C to -22°C, giving a very thick translucid gel. The reaction was quenched with saturated aq. NH₄CI (250 mL) and EtOAc (300 mL). The product was extracted with EtOAc, washed with H₂O and brine, and dried over MgSO₄. Purification by flash chromatography (20% to 30% EtOAc in hexanes) gave 16.8 g (68%) of the title compound. Step 13: Methyl 1-(((1(R)-(3-(hydroxymethyl)phenyl)-3- (2-(1-hydroxy-1-methyl)ethyl)phenyl)thio)- methyl)eyelopropaneacetate

To the hydroxy ester from Step 12 (9.02 g, 17.1 mol) in anhydrous MeOH (60 mL) under nitrogen was added pyridine (50 /μL) followed by PPTS (1.1 g, 4.3 mmol). The reaction mixture was stirred 3.5 hours at 55ºC, then at r.t. overnight before

concentrating in vacuo. The residue was diluted with EtOAc (500 mL) and washed with H₂O, saturated aq.

NaHCO₃, NaH₂PO₄ buffer (pH = 4.5) and with brine.

After drying over MgSO₄ and evaporation of the solvents, the residue was purified by flash

chromatography (40% to 60% EtOAc in hexanes) giving 6.85 g (91%) of the title compound.

¹H NMR (CD₃COCD₃): δ 7.41 (2H, m), 7.27 (3H, m), 7.09 (3H, m), 4.63 (2H, d), 4.19 (1H, t), 3.95 (1H, t), 3.88 (1H, s), 3.57 (3H, s.), 3.1 (1H, ddd), 2.8 (1H, ddd), 2.5 (2H, s), 2.4 (2H, d), 2.17 (2H, m), 1.52 (6H, s), 0.52-0.35 (4H, m).

Step 14: Methyl 1-((((1R)-3-(formyl)phenyl)-3-(2- (1-hydroxy-1-methyl)ethyl)phenyl)thio)- methyl)cyclopropaneacetate

To the dihydroxy ester from Step 13 (6.8 g, 15.4 mmol) in EtOAc (150 mL) at 50ºC was added MnO₂ (6.7 g, 76.8 mmol). After stirring for 30 minutes at 50°C more MnO₂ (6.7 g) was added, and 30 minutes later, a third portion of Mn2₂ (6.7 g) was added. An hour later, the warm reaction mixture was filtered through celite and the cake was washed with

additional EtOAc. Evaporation of the solvents gave the desired aldehyde 5.62 g (83 %).

¹H NMR (CD₃COCD₃): δ 10.4 (1H, s), 7.9 (1H, bs), 7.8 (2H, m), 7.58 (1H, t), 7.38 (1H, bd), 7.1 (3H, m), 4.1 (1H, t), 3.54 (3H, s), 3.13 (1H, ddd), 2.85 (1H, ddd), 2.51 (2H, s), 2.49 (2H, d), 2.2 (2H, m), 1.51 (6H, s), 0.52-0.32 (4H, m).

Step 15: Methyl 1-(((1(R)-((3-(2-(2-benzothiazolyl)- ethenyl)phenyl)-3-(2-(1-hydroxy-1-methyl)- ethyl)phenyl)propyl)thio)methyl)cyclopropaneacetate

To a suspension of the phosphonium salt from Step 2 (560 mg, 1.14 mmol) in dry THF (3 mL) at -78ºC was added BuLi (0.45 mL, 1.6M solution in hexane). The mixture was stirred at -78ºC for 1 hr, warmed to -25°C for 30 min and then cooled to -78ºC. The aldehyde from Step 14 (250 mg, 0.57 mol) was added. The mixture was stirred at -78ºC for 30 min, warmed to 25ºC for 15 min. Aqueous NH₄OAC was added and the mixture was extracted with EtOAc. The organic extract was washed with brine, dried over MgSO₄ and

concentrated to an oil. Chromatography of the crude oil on silica gel (eluted with 30% EtOAc in hexane) gave 270 mg (82%) of the title compound. Step 16: Sodium 1-(((1(R)-((3-(2-(2-benzothiazolyl) ethenyl)phenyl)-3-(2-(1-hydroxy-1- methyl) ethyl)phenyl)propyl)thio)methyl)cyclopropaneacetate

To a solution of the ester of Step 15 in THF (1 mL) and MeOH (1 mL) was added aqueous NaOH (1N, 1.4 mL). The mixture was stirred at 25ºC for 20 hr. NH₄CI was added and the mixture was extracted with EtOAc. The organic extract was washed with brine, dried over MgSO₄ and concentrated to an oil.

Chromatography of the crude oil on silica gel (eluted with 20% EtOAc/5% HOAc in hexane) gave 240 mg (92%) of the corresponding acid. To this acid in 3 mL EtOH was added NaOH (1N, 1.0 equivalent). The solvent was evaporated and the product was lyopholysed to give the title compound. Exact mass calculated for

C₃₃H₃₅NO₃S₂Na (M+1): 580.1957; found: 580.1956.

¹H NMR (250 MHz, CD₃COCD_3.) : δ 0.2-0.6 (4H, m), 1.51 (6H, s), 2.2-2.4 (4H, m), 2.6-2.8 (3H, m), 3.2 (1H, m), 4.1 (1H, t), 6.9-7.2 (3H, m), 7.3-7.6 (6H, m), 7.65 (2H, d), 7.7 (1H, s), 8.0 (2H, dd).

Anal. Calc'd for C₃₃H₃₄NO₃S₂Na•2H₂O:

C, 64.37; H, 6.22; N, 2.27; S, 10.41; Na, 3.73.

Found :

C, 64.00; H, 6.30; N, 2.61; S, 10.22; Na, 4.06. EXAMPLES 2-6

Using the above methodology and that described in Schemes 1, 2, and 4, the compounds of Examples 2-6 were prepared. Analytical data are listed in Table II.

High Resolution Mass Spec . Analysis

Ex. Formula Calc ' d Found

2 C₃₃H₃₃NFO₃S₂Na+H⁺ 598. 1859 598.1861

3 C₃₃H₃₃NClO₃S₂Na 614.1566 614.1567

5 C₃₃H₃₂NF₂O₃S₂Na+H⁺ 616.1767 616.1768

6 C₃₄H₃₆NO₄S₂Na+H⁺ 610.2061 610.2062

Claims

WHAT IS CLAIMED IS:

1. A compound of the Formula:

wherein:

R¹ is H, halogen, CN, lower alkyl, cyloakyl,

polyhalo lower alkyl, lower alkoxy, lower alkoxy lower alkyl, lower alkylthio lower alkyl, lower alkenyl, substituted or unsubstituted phenyl, pyridyl, thiazolyl, oxazolyl, furanyl or thienyl, or adjacent RI'S and the carbons through which they are attached may form a saturated ring of 5 to

10 carbon atoms;

R² is lower alkyl, lower alkenyl, lower alkynyl,

-CF₃, -CH₂F, -CHF₂, -CH₂CF₃, substituted or unsubstituted phenyl, substituted or unsubstituted benzyl, substituted or unsubstituted 2-phenethyl, or two R² groups joined to the same carbon may form a saturated ring of up to 8 members containing 0 to 2 heteroatoms chosen from O, S, and N; R³ is H or R²: _CR3_R22 may be the radical of a standard amino acid;

R⁴ is halogen, -NO₂, -CN, -OR³, -SR³, NR³R³ ,

NR³C(O)R⁷, or R³;

R⁵ is H, halogen, -NO₂, -N₃, -CN, -SR², -NR³R³,

-OR³, lower alkyl, or -C(O)R³;

R⁶ is -(CH₂)_S-C(R⁷R⁷)-(CH₂)_S-R⁸ or -CH₂C(O)NR¹²R¹²;

R⁷ is H or lower alkyl;

R⁸ is A) a monocyclic or bicyclic heterocyclic

radical containing from 3 to 12 nuclear carbon atoms and 1 or 2 nuclear heteroatoms selected from N, S or O and with each ring in the heterocyclic radical being formed of 5 or 6 atoms, or

B) the radical W-R⁹;

R⁹ contains up to 20 carbon atoms and is (1) an alkyl group or (2) an alkylcarbonyl group of an organic acyclic or monocyclic carboxylic acid containing not more than 1 heteroatom in the ring;

R¹⁰ is -SR¹¹, -OR¹², or -NR¹²R¹²;

R¹¹ is lower alkyl, -C(O)R¹⁴, unsubstituted phenyl, or unsubstituted benzyl;

R¹² is H, R¹¹, or two R¹² groups joined to the same

N may form a saturated ring of 5 or 6 members containing up to two heteroatoms chosen from 0, S, and N;

R¹³ is lower alkyl, lower alkenyl, lower alkynyl,

-CF₃, or substituted or unsubstituted phenyl, benzyl, or 2-phenethyl;

R¹⁴ is H or R¹³;

R¹⁵ is R³ or halogen;

R¹⁶ is H, lower alkyl, or OH; R¹⁷ is lower alkyl, lower alkenyl, lower alkynyl, or substituted or unsubstituted phenyl, benzyl, or 2-phenethyl;

R¹⁸ is lower alkyl, lower alkenyl, lower alkynyl,

-CF₃, or substituted or unsubstituted phenyl, benzyl, or 2-phenethyl;

R¹⁹ is lower alkyl, lower alkenyl, lower alkynyl,

-CF₃, or substituted or unsubstituted phenyl, benzyl, or 2-phenethyl;

R²⁰ is H, lower alkyl, substituted or unsubstituted phenyl, benzyl, phenethyl, or pyridinyl, or two R²⁰ groups joined to the same N may form a saturated ring of 5 or 6 members containing one to two heteroatoms chosen from O, S, and N;

R²¹ is H or R¹⁷;

R²² is R⁴, CHR⁷OR³, or CHR⁷SR²;

m and m' are independently 0-8;

p and p' are independently 0-8;

m + p is 1-10 when X² is O , S , S(O) , or S(O)₂;

m + p is 0-10 when X² is CR³R¹⁶ or a bond;

m' + p' is 0-10;

s is 0-3;

Q¹ is -C(O)OR³, 1H (or 2H)-tetrazol-5-yl,

-C(O)OR⁶, -C(O)NHS(O)₂R¹³, -CN,

-C(O)NR¹²R¹², NR²¹S(O)₂R¹³,

-NR¹²C(O)NR¹²R¹², -NR²¹C(O)R¹⁸,

0C(O)NR¹²R¹², -C(O)R¹⁹, -S(O)R¹⁸, -S(O)₂R¹⁸, -S(O)₂NR¹²R¹², -NO₂, NR²¹C(O)OR¹⁷, -C(NR¹²R¹²)=NR¹², or -C(R¹³)=NOH; or if Q¹ is C(O)OH and R²² is -OH, -SH, CHR⁷OH or -NHR³, then Q¹ and R²² and the carbons through which they are attached may form a heterocyclic ring by loss of water;

Q² is OR³;

W is O, S, or NR³;

X¹ is O, S, -S(O)-, -S(O)₂-, -N(R³)-, or -CR³R³-;

X² and X³ are independently O, S, S(O), S(O)_2.

CR³R¹⁶, or a bond;

Y is -CR³=CR³-, -C≡C-, -CR³R³-X¹-, -X¹-CR³R³-,

-CR³R³-X¹-CR³R³-,

-C(O)-, -NR³C(O)-, -C(O)NR³-, O, S, NR³ , or

;

Z¹ and Z² are independently -HET(-R³-R⁵)- or a bond;

HET is the diradical of a benzene, a pyridine, a furan, or a thiophene; or a pharmaceutically acceptable salt thereof A compound of Claim 1 of the Formula:

wherein:

R¹ is H, halogen, CF3, or lower alkoxy;

R²² is R³, -CH₂OR³, or -CH₂SR²;

Q¹ is -C(O)OH, 1H(or 2H)-tetrazol-5-yl,

-C(O)NHS(O)₂R¹³, -C(O)NR¹²R¹², or -NHS(O)₂R¹³; m' is 2 or 3;

p' is 0 or 1; and

m + p is 1-5;

or a pharmaceutically acceptable salt thereof.

A compound of Claim 1 of the Formula:

wherein the substituents are as follows: EX. * R¹ R¹ Y A

1 R H H CH=CH (CH₂)₂(1,2)phe)C(Me)₂OH SCH₂C(CH₂)₂CH₂CO₂H

2 R 5-F H CH=CH (CH₂)₂(1,2-phe)C(Me)₂OH SCH₂C(CH₂)₂CH₂CO₂H

3 R 5-C1 H CH=GH (CH₂)₂(1,2-phe)C(ME)₂OH SCH₂C(CH₂)₂CH₂CO₂H

4 R 5-CF₃ H CH=CH (CH₂)₂(1,2-phe)C(ME)₂OH SCH₂C(CH₂)₂CH₂CO₂H

5 R 5-F 6-F CH=CH (CH₂)₂(1,2-phe)C(ME)₂OH SCH₂C(CH₂)₂CH₂CO₂H

6 R H 6-OMe CH=CH (CH₂)₂(1,2-phe)C(ME)₂OH SCH₂C(CH₂)₂CH₂CO₂H

7 R 5-F 6-CF₃ CH₂CH₂ (CH₂)₂(4-C1-1,2-phe)C(ME)₂OH OCH₂C(CH₃)₂CH₂CO₂H

8 S 5-F 6-CF, CH₂O (CH₂)₂(4-C1-1,2-phe)C(ME)₂OH OCH₂CH(CH₃)CH₂Tz

9 R 5-CF₃ 6-F CH(-CH₂-)CH (CH₂)₂(4-F-1,2-phe)C(ME)₂OH SCH₂CH(C₂H₅)CH₂CONMe₂

10 S 5-CF₃ 6-CF₃ CH(CH₃)CH(CH₃) (CH₂)₂(4-F-1,2-phe)CMePhOH SCH₂CH₂CO₂H

11 RS H 6-F CH(-C(CH₃)₂-)CH (CH₂)₂(3-C1-1,2-phe)CHMeOH SCH₂CH₂CONHS(O)₂Ph

12 R 5-F 6-C1 CH₂S (CH₂)₂(5-F-1,2-phe)CMeCF₃OH SCH₂CH₂CONHS(O)₂CH₃

13 RS 5-C1 6-GF CH(CH₃) CH₂ (6-CF₃-1,2-phe)CHCF₃OH SCH₂CH₂CONHS(O)₂CF₃ 14 S 5-C1 6-C1 CH=CH (CH₂)₂(4-CF₃-1,2-phe)C(CF₃)₂OH SCH₂C(CH₂)₂CH₂CONHS(O)₂Ph

15 R 5-F 6-F CH₂CH₂ (CH₂)₂(4-F-1,3-phe)CMeEtOH CH₂CH₂C(CH₃)₂CO₂H

16 R 5-F H CH₂CH₂ (CH₂)₂(4-F-1,4-phe)C(CH₂)₂OH SCH₂CH(C₂H₅)Tz

17 R 5-C1 H CH=CH (CH₂)₂(4-F-1,2-phe)C(CH₂)₃OH SCH₂C(CH₂)₂NHS(O)₂CF₃

18 S 5-F H CH=CH (CH₂)₂(4-F-1,2-phe)C(CH₂)₄OH SCH₂C(CH₂)₃CH₂CO₂H

19 R 5-C1 H CH₂CH₂ (CH₂)₂(4.-F-1,2-phe)C(CH₂)₅OH SCH₂C(CH₂)₄CH₂CO₂H

20 S 5-CF₃ H CH₂O (CH₂)₂(2,5-fur)C(Me)₂OH SCH₂C(CH₂)₅CH₂CO₂H

21 RS 5-F 6-F CH(-CH₂-)CH (CH₂)₂(1,2-phe)C(Me)₂OH SCH₂C(CH₃)₂CH₂CO₂H

22 R 5-F 6-F CH(CH₃)(CH(CH₃) (CH₂)₂(2,5-thio)C(Me)₂OH SCH₂CH(CH₃)CH₂Tz

23 R 5-F H CH(-C(CH₃)₂-)CH (CH₂)₂(2,6-pye)C(Me)₂OH SCH₂CH(C₂H₅)CH₂CONMe₂

24 R 5-C1 H CH₂S (CH₂)₂(2,4-pye)C(Me)₂OH SCH₂CH₂CO₂H

25 R 4-c-Bu H CH=CH (CH₂)₂(1,2-phe)C(Me)₂OH SCH₂C(CH₂)₂CH₂CO₂H

26 R 4-CN H CH=CH (CH₂)₂(1,2-phe)C(Me)₂OH SCH₂C(CH₂)₂CH₂CO₂H

4. A pharmaceutical compositon comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

5. The pharmaceutical composition of Claim 4 additionally comprising an effective amount of a second active ingredients selected from the group consisting of non-steroidal anti-inflammatory drugs; peripheral analgesic agents; cycloxygenase

inhibitors; leukotriene antagonists; leukotriene biosynthesis inhibitors; H₁- or H2-receptor

antagonists; antihistaminic agents; prostaglandin antoganists; and ACE antagonists,

6. A pharmaceutical composition of Claim 5, wherein the second active ingredient is a

non-steroidal anti-inflammatory drug.

7. A pharmaceutical composition of Claim 6, wherein the weight ratio of said compound of Claim 1 to said second active ingredient ranges from about 1000:1 to 1:1000.

8. A method of preventing the synthesis, the action, or the release of SRS-A or leukotrienes in a mammal which comprises administering to said mammal an effective amount of a compound of Claim 1.

9. The method of Claim 8 wherein the mammal is man.

10. A method of treating asthma in a mammal comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

11. The method of Claim 10 wherein the mammal is man.

12. A method of treating inflammatory diseases of the eye in mammal which comprises administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Claim 1.

13. A compound of formula (I), or a pharmaceutically acceptable salt, thereof, as defined in claim 1, 2 or 3, for use in preventing the synthesis, the action, or the release of SRS-A or leukotrienes in a mammal.

14. Use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in claim 1, 2 or 3, in the manufacture of a medicament for treating asthma or inflammatory diseases of the eye.

15. A leukotriene antagonist pharmaceutical composition comprising an acceptable leukotriene antagonistic amount of a compound of formula (I), or a pharmaceutically acceptable salt thereof, as defined in claim 1, 2 or 3, in association with a pharmaceutically acceptable carrier.